Fight For Lipitor: FDA Calls For Dismissal Of Mylan's Plea On Ranbaxy's AIP
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's court filing discloses that the agency and Ranbaxy are in ongoing discussions to resolve the issues described in earlier letter invoking AIP, used when there are significant data integrity issues in drug applications.
You may also be interested in...
Lipitor Generics: FDA Says Mylan Has No Standing To Sue (Until June 28?)
FDA is using a recent court decision involving ViroPharma’s antibiotic Vancocin to argue for dismissal of a Mylan Pharmaceuticals Inc. lawsuit that seeks a determination on generic marketing exclusivity rights for Pfizer’s Lipitor.
Lipitor Generics: FDA Says Mylan Has No Standing To Sue (Until June 28?)
FDA is using a recent court decision involving ViroPharma’s antibiotic Vancocin to argue for dismissal of a Mylan Pharmaceuticals Inc. lawsuit that seeks a determination on generic marketing exclusivity rights for Pfizer’s Lipitor.
Mylan Sues FDA Alleging Inaction And Failure To Share Clarity On Ranbaxy's Atorvastatin Filings
MUMBAI - Two months after settling a patent litigation with Pfizer Inc. for cholesterol-reducing agent Lipitor (atorvastatin), generic drugs major Mylan Pharmaceuticals Inc. has charged that U.S. FDA's failure to decide and disclose critical information related to Ranbaxy Laboratories' Ltd. abbreviated new drug application for atorvastatin is "unlawful, arbitrary and capricious.